secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nautilus Biotechnology, Inc. (NAUT)
CIK:        0001808805
Form:       8-K
Filed at:   2025-07-31T23:59:59+00:00
Accession:  0001808805-25-000069
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nautilus Q2 net loss narrows to $15.0M; cash $179.5M; platform milestone
------------------------------------------------------------------------

- Operating expenses $17.1M, down 18% YoY from $20.8M.
- Net loss $15.0M improved from $18.0M loss in Q2 2024.
- Cash, equivalents and investments $179.5M as of June 30, 2025.
- Published first scientific manuscript validating Iterative Mapping method for proteoform measurement.
- Signed two collaborations to study Tau proteoforms in Alzheimer's disease.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808805/000180880525000069/0001808805-25-000069-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808805/000180880525000069/naut-20250731.htm
  HTML page:      https://secwatch.observer/filing/0001808805-25-000069

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer